Of note, renal pathology at presentation (i.e., MCD or FSGS) and the use of a renin-angiotensin-aldosterone system blocking agent did not modify the delay to the best renal response (data not shown). This evidence concerns the gene REN and focal segmental glomerulosclerosis.